Gesa Schalk

1.1k total citations
13 papers, 247 citations indexed

About

Gesa Schalk is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Nephrology. According to data from OpenAlex, Gesa Schalk has authored 13 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 4 papers in Nephrology. Recurrent topics in Gesa Schalk's work include Kidney Stones and Urolithiasis Treatments (7 papers), Porphyrin Metabolism and Disorders (4 papers) and Biomedical Research and Pathophysiology (4 papers). Gesa Schalk is often cited by papers focused on Kidney Stones and Urolithiasis Treatments (7 papers), Porphyrin Metabolism and Disorders (4 papers) and Biomedical Research and Pathophysiology (4 papers). Gesa Schalk collaborates with scholars based in Germany, United States and United Kingdom. Gesa Schalk's co-authors include Bernd Höppe, Jaap W. Groothoff, Michael Kirschfink, Cyrill Wehling, Graham Lipkin, Burkhard Tönshoff, Pierre Cochat, Sander F. Garrelfs, David McDougall and Karim Kentouche and has published in prestigious journals such as Kidney International, Journal of the American Society of Nephrology and Frontiers in Immunology.

In The Last Decade

Gesa Schalk

13 papers receiving 241 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gesa Schalk Germany	8	97	94	81	77	41	13	247
Christof Aigner Austria	9	120 1.2×	69 0.7×	28 0.3×	92 1.2×	37 0.9×	37	249
L Moulonguet France	5	191 2.0×	27 0.3×	54 0.7×	277 3.6×	110 2.7×	12	363
Ramón Vilalta Spain	9	282 2.9×	42 0.4×	44 0.5×	256 3.3×	94 2.3×	21	429
Anna Zito Italy	6	107 1.1×	36 0.4×	39 0.5×	125 1.6×	43 1.0×	18	210
Ying Siow Tan United States	8	169 1.7×	61 0.6×	20 0.2×	36 0.5×	69 1.7×	10	293
L. Harman United States	6	26 0.3×	188 2.0×	24 0.3×	26 0.3×	19 0.5×	10	309
Emma Diletta Stea Italy	7	89 0.9×	21 0.2×	22 0.3×	74 1.0×	31 0.8×	14	169
Jean‐Baptiste Gibier France	9	29 0.3×	109 1.2×	30 0.4×	48 0.6×	19 0.5×	36	241
Geoff Yu Zhang Australia	10	227 2.3×	48 0.5×	19 0.2×	118 1.5×	17 0.4×	17	332
Pei‐Chi Kao United States	8	42 0.4×	75 0.8×	37 0.5×	9 0.1×	17 0.4×	28	230

Countries citing papers authored by Gesa Schalk

Since Specialization

Citations

This map shows the geographic impact of Gesa Schalk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gesa Schalk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gesa Schalk more than expected).

Fields of papers citing papers by Gesa Schalk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gesa Schalk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gesa Schalk. The network helps show where Gesa Schalk may publish in the future.

Co-authorship network of co-authors of Gesa Schalk

This figure shows the co-authorship network connecting the top 25 collaborators of Gesa Schalk. A scholar is included among the top collaborators of Gesa Schalk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gesa Schalk. Gesa Schalk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Lieske, John C., Gema Ariceta, Jaap W. Groothoff, et al.. (2025). PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1. Kidney International Reports. 10(6). 1993–2002. 1 indexed citations

Groothoff, Jaap W., Anne‐Laure Sellier‐Leclerc, Justine Bacchetta, et al.. (2024). Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3. Kidney International Reports. 9(5). 1387–1396. 11 indexed citations

Goldfarb, David S., et al.. (2023). Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). Urolithiasis. 51(1). 80–80. 31 indexed citations

Ariceta, Gema, Laure Collard, Saoussen Abroug, et al.. (2022). ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria. Pediatric Nephrology. 38(2). 403–415. 13 indexed citations

Gimpel, Charlotte, Jutta Gellermann, Gesa Schalk, et al.. (2022). Early clinical course of biopsy-proven IgA vasculitis nephritis. BMC Pediatrics. 22(1). 570–570. 2 indexed citations

Höppe, Bernd, Annelize Koch, Pierre Cochat, et al.. (2021). Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney International. 101(3). 626–634. 67 indexed citations

Frishberg, Yaacov, Sally A. Hulton, Pierre Cochat, et al.. (2020). Results from the Ongoing Phase 2 Open-Label Extension Study of Lumasiran, an Investigational RNAi Therapeutic, in Patients with Primary Hyperoxaluria Type 1 (PH1). Journal of the American Society of Nephrology. 31(10S). 520–521. 2 indexed citations

Coenen, Martin, Gesa Schalk, Pierre Cochat, et al.. (2020). PHYOX3: A Long-Term, Open-Label Extension Trial of Nedosiran in Patients with Primary Hyperoxaluria Type 1, 2, or 3. Journal of the American Society of Nephrology. 31(10S). 515–515. 3 indexed citations

Michael, Mini, Georges Deschênes, Pierre Cochat, et al.. (2020). ILLUMINATE-B, a Phase 3 Open-Label Study to Evaluate Lumasiran, an RNAi Therapeutic, in Young Children with Primary Hyperoxaluria Type 1 (PH1). Journal of the American Society of Nephrology. 31(10S). 515–515. 5 indexed citations

10.

Moos, Seraina von, Gesa Schalk, Thomas Mueller, & Guido F. Laube. (2019). Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity. Immunity & Ageing. 16(1). 9–9. 12 indexed citations

11.

Zhao, Fei, S. Lindner, Andrea Hartmann, et al.. (2019). C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases. Frontiers in Immunology. 10. 1030–1030. 13 indexed citations

12.

Wehling, Cyrill, Oliver Amon, Martin Bommer, et al.. (2016). Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clinical & Experimental Immunology. 187(2). 304–315. 74 indexed citations

13.

Schalk, Gesa, Michael Kirschfink, Cyrill Wehling, et al.. (2015). A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab. Pediatric Nephrology. 30(6). 1039–1042. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact